
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 10, 2016

NantHealth, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-37792
(Commission
File Number)

27-3019889
(IRS Employer
Identification No.)

9920 Jefferson Boulevard
Culver City, California 90232
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (310) 883-1300

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure.

NantHealth, Inc.'s ("NantHealth") President, Robert Watson, will participate in the Canaccord Genuity Growth Conference in Boston on Wednesday, August 10, 2016. During the conference and in separate sessions with analysts and investors, Mr. Watson will refer to a slide presentation. A copy of the slide presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation dated August 10, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NANTHEALTH, INC.

By: /s/ Paul Holt
Paul Holt
Chief Financial Officer

Date: August 10, 2016

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation dated August 10, 2016.



NantHealth Investor Presentation

Next-generation, evidence-based, personalized healthcare company
August 2016

NASDAQ: NH
Robert Watson, President

Confidential Copyright © Do not distribute

Disclosure Statements

This presentation has been prepared by NantHealth, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any information or statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.

These materials and related materials and discussions may contain forward-looking statements that are based on the Company's current expectations, and projections and forecasts about future events and trends that the Company believes may affect its business, financial condition, operating results and growth prospects. Forward-looking statements are subject to substantial risks, uncertainties and other factors, including but not limited to (1) the structural change in the market for healthcare in the United States, including uncertainty in the healthcare regulatory framework and regulatory developments in the United States and foreign countries; (2) the evolving treatment paradigm for cancer, including physicians' use of molecular information and targeted oncology therapeutics and the market size for molecular information products; (3) physicians' need for precision medicine products and any perceived advantage of our solutions over those of our competitors, including the ability of our comprehensive platform to help physicians treat their patients' cancers; (4) our ability to generate revenue from sales of products enabled by our molecular and biometric information platforms to physicians in clinical settings; (5) our ability to increase the commercial success of our sequencing and molecular analysis solution; (6) our plans or ability to obtain reimbursement for our sequencing and molecular analysis solution, including expectations as to our ability or the amount of time it will take to achieve successful reimbursement from third-party payors, such as commercial insurance companies and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid; (7) our ability to effectively manage our growth, including the rate and degree of market acceptance of our solutions; and (8) our ability to offer new and innovative products and services, attract new partners and clients, estimate the size of our target market, and maintain and enhance our reputation and brand recognition.

The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representation or warranty, express or implied, is given as to the completeness or accuracy of the information or opinions contained in this document and neither the Company nor any of its directors, members, officers, employees, agents or advisers accepts any liability for any direct, indirect or consequential loss or damage arising from reliance on such information or opinions. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance.

We own or have rights to trademarks and service marks that we use in connection with the operation of our business. NantHealth, Inc. and our logo as well as other protected brands. Solely for convenience, our trademarks and service marks referred to in this presentation are listed without the (sm) and (TM) symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Additionally, we do not intend for our use or display of other companies' trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. We have indicated with (TM) symbols where these third party trademarks are referred to in this presentation.

This presentation includes certain financial measures not based on accounting principles generally accepted in the United States, or non-GAAP measures. These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

About NantHealth




"Our vision is to overcome traditional healthcare barriers and harness the power of innovation to achieve cutting edge advancements."

*Patrick Soon-Shiong, M.D., FRCS(C), FACS
CEO and Chairman, NantHealth*


A next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses.

- Founded by Dr. Patrick Soon-Shiong in 2010
- IPO in June 2016 (NASDAQ: NH)
- 850+ associates worldwide
- Headquarters: Culver City, CA
- Worldwide offices: Boston (MA), Dallas (TX), Philadelphia (PA), Cleveland (OH), Panama City (FL), Melbourne (FL), Phoenix (AZ), Hyderabad (India), London (UK), Belfast (N. Ireland)

Multi-Billion Dollar, Rapidly Growing Market Opportunity



Vision Toward Integrated Learning System for Healthcare



Comprehensive Solutions for Providers, Payors & Employers

GPS Cancer™



Genomic Proteomic Spectrometry

Unique, comprehensive molecular test

- Quantitative proteomics
- Whole genome (DNA) and transcriptome (RNA) sequencing
- Tumor-normal matching
- CLIA-certified, CAP-accredited



NantHealth Technology Solutions

Oncology decision support (eviti)

Patient portal

Care coordination

Device connectivity (DeviceConX)

Clinical learning and analytics

Provider portal

Payer-provider collaboration (NaviNet Open)

Vital signs collection (VitalsConX)


Rich web-based and mobile apps for knowledge, delivery, and payor domains

NantOS™

Connectivity to 250+ clinical and financial systems, 300+ medical devices, 200+ health and wellness sensors

Platform with rich connectivity across ecosystem

GPS Cancer: Enable utilization of lower cost chemotherapy with knowledge of quantitative proteomic chemo-resistance or chemo-sensitivity biomarkers before treatment begins



Our Global Scale

Highly unique infrastructure and expertise with global scale

>100,000,000

Covered lives on our Provider and Payor Platforms

~30,000,000

Payor-provider transactions monthly

>75%

Of U.S. oncology practices have used our decision support platform

10s of Billions

Of vital signs captured annually

>30,000

Unique in hospital medical devices integrated

>60%

Of U.S. physicians' offices are connected to our payor-provider collaboration solution

>2,000

Hospitals use NantOS app workflow provider portal

~13,000

Clinical trials updated weekly

>10 Million

Lives covered by providers and payers with three years of longitudinal data


>850

Employees with > 115 in a clinical function

Leading Payor Clients Nationwide



Leading Health System Clients Worldwide



Experienced Management Team



Q2 2016 Business Highlights

- IPO on June 2, 2016 (NASDAQ: NH)
- Commercial availability of GPS Cancer, leading comprehensive molecular test integrating quantitative proteomics and genomics
 - Growing adoption from physicians nationwide and internationally
 - 180,000 patients with cancer covered by a payer for GPS testing at end Q2 2016
- First international distributor for GPS Cancer
- New clients signed for eviti and NantOS applications
 - Banner Health Network
 - Sanford Health
- Multiple client go-lives on NaviNet and DeviceConX applications
 - Montefiore Medical Center
 - Capital Region of Denmark Phase 1
 - AmeriHealth Caritas and others

Q2 2016 Financial Highlights

Three months ended June 30, 2016

- **Net revenue** = \$31.5 million
 - Up from \$11.8 million in Q2 2015; 167% growth
- **Gross profit** = \$9.3 million
 - Up from \$5.5 million in Q2 2015; 69% growth
- **Net profit** = (\$54.1 million)
- **Total bookings** = \$12.0 million
- **EPS (GAAP)** = (\$0.52)
- **EPS (non-GAAP)** = (\$0.15)

Six months ended June 30, 2016

- **Net revenue** = \$50.9 million
 - Up from \$23.5 million in H1 2015; 117% growth
- **Gross profit** = \$15.7 million
 - Up from \$11.6 million in H1 2015; 35% growth
- **Net profit** = (\$87.3 million)
- **Total bookings** = \$34.0 million
- **EPS (GAAP)** = (\$0.86)
- **EPS (non-GAAP)** = (\$0.33)

Company Summary

A next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses.

Exchange / Ticker	NASDAQ: NH
Share Price (52-week range)	August 1, 2016: \$9.98 (52-week high – \$21.00; low - \$9.79)
Common shares outstanding	120.7 million
Market cap	\$1.2 billion
Cash	\$95.2 million (June 30, 2016)
Bank debt	\$112.7 million (June 30, 2016)
Net revenue	Q2 2016: \$31.5 million; H1 2016: \$50.9 million
Gross profit	Q2 2016: \$9.3 million; H1 2016: \$15.7 million
Net profit	Q2 2016: (\$54.1 million); H1 2016: (\$87.3 million)
Number of associates worldwide	850+



Thank You